Program: Oral and Poster Abstracts
Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III
Methods: From September 2014-March 2015, a purposeful sample of 30 patients with a diagnosis of ALL treated at Children's Hospital of Los Angeles were recruited to this IRB-approved study either prior to starting Induction phase or during Maintenance phase. Tanner Stage was classified as ≤2 or ≥4, excluding Tanner Stage 3. Vincristine blood levels were obtained around the first dose during Induction or any single monthly dose during Maintenance at pre-specified time points: 0 min, 10 min, 30 min, 1 hour, 12 hour (Induction only), and 24 hours. For all patients, the vincristine dose was 1.5 mg/m2(max 2 mg). Vincristine levels were determined by high performance liquid chromatography. Mean vincristine clearance was compared using the independent T-test. Univariate and multivariate linear regression analysis via backward selection was performed using Tanner Stage, age, sex, BMI, fluconazole exposure, and treatment phase as predictors. P-values were two-sided with significance set at < 0.05.
Results: The age range was 1-24 yrs (< 10 yrs, n=12; 10+ yrs, n=18). 15 (50.0%) patients were female; and 26 (86.7%) were Hispanic. BMI was underweight/normal for 20 (66.7%). Fluconazole was being administered to 19 (63.3%). Tanner Stage was ≤ 2 for 14 patients (46.7%) and ≥ 4 for 16 (53.3%). Mean vincristine clearance (standard error) for the Tanner ≤ 2 and ≥ 4 groups was 61.14 (18.42) and 68.75 (10.05) L/h*m2, respectively (p=0.71). As summarized in Tables 1 and 2, in both univariate and multivariate analyses no predictors, including Tanner Stage, were associated with vincristine clearance.
Conclusions: In this pilot study, we were unable to detect an association between vincristine clearance and Tanner Stage. These data suggest that even when using a measure more reflective of physiological maturity than age, substantial developmental differences in vincristine clearance appear to be lacking. This calls into question the potential explanation of altered clearance for the increased VRNT observed in AYAs, and suggests that future investigations should be directed toward potential developmental differences in vincristine pharmacodynamics. Our data may have implications for understanding other differences in chemotherapy toxicity observed in AYAs.
Table 1: Univariate Analysis of Vincristine Clearance
Predictor |
Clearance Unit: L/h*m2 |
|
Diff (SE) |
F-test P-value |
|
Tanner stage ≥4 vs. ≤2 |
7.615 (20.279) |
0.71012 |
Age 10+ vs. <10 |
13.523 (20.545) |
0.51577 |
Phase of therapy Maintenance vs. Induction |
-6.971 (20.288) |
0.73371 |
Gender Female vs. Male |
4.307 (20.269) |
0.83326 |
BMI group OW/Obese vs. UW/Normal |
9.931 (21.434) |
0.64669 |
Fluconazole use Yes vs. No |
-2.799 (21.041) |
0.89512 |
Table 2: Multivariate analysis of Vincristine Clearance
|
Model #1 |
Model # 2 |
||||
Endpoint |
Predictor |
Diff (SE) |
LRT P-value |
Predictor |
Diff (SE) |
LRT P-value |
Clearance Unit: L/h*m2 |
Age 10+ vs <10 |
21.4211 (23.3859) |
0.3380 |
Tanner stage ≥4 vs. ≤2 |
13.8334 (23.1741) |
0.5306 |
Phase Maintenance vs Induction |
-16.7252 (22.9644) |
0.4449 |
Phase Maintenance vs Induction |
-13.3936 (23.1741) |
0.5436 |
Disclosures: No relevant conflicts of interest to declare.
See more of: Acute Lymphoblastic Leukemia: Clinical Studies
See more of: Oral and Poster Abstracts
*signifies non-member of ASH